Looking Into 10x Genomics's Return On Capital Employed
Portfolio Pulse from Benzinga Insights
10x Genomics reported Q1 sales of $134.28 million and a loss of $50.75 million, resulting in a 194.78% decrease from last quarter. The company posted a negative Return on Capital Employed (ROCE) of -0.06%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.44, missing analyst predictions of $-0.37.
May 24, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
10x Genomics reported a Q1 loss of $50.75 million and a negative ROCE of -0.06%, indicating inefficient capital allocation. The company's Q1 EPS of $-0.44 missed analyst predictions of $-0.37.
10x Genomics reported a significant loss in Q1 and a negative ROCE, suggesting inefficient capital allocation. This could negatively impact the stock price in the short term. Additionally, the company's Q1 EPS missed analyst predictions, which may further contribute to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100